Statistical Considerations in the Design, Conduct, and Analysis of Antiemetic Clinical Trials
Various aspects of trial design and planning for clinical testing of antiemetic therapies administered to cancer patients are considered. It is generally felt that a randomized double-blind parallel-arm design is the best. Ways of achieving adequate power of such studies are discussed briefly, as is the need for previous identification of primary and secondary end points. Finally, summary recommendations are given.
KeywordsInterim Analysis Adequate Power Multiple Cycle Emetogenic Chemotherapy Antiemetic Therapy
Unable to display preview. Download preview PDF.
- 3.Ballatori E, Roila F, Del Favero A (1996) Methodology of antiemetic trials. In: Tonato M (ed) Antiemetics in the supportive care in cancer. Springer, Berlin Heidelberg New York, pp 35–47Google Scholar
- 4.Bechhofer RE, Santner TJ, Goldsman DM (1995) Design and analysis of experiments for statistical selection, screening, and multiple comparisons. Wiley, New YorkGoogle Scholar
- 7.Bonneterre J, Hecquet B, Adenis A, Fournier C, Pion JM, Demaille A (1991) How do patients and physicians decide which antiemetic is the best in a cross-over study? Proc ASCO 10: 323Google Scholar
- 9.Geller NL (1987) Planned interim analysis and its role in cancer clinical trials. J Clin Oncol 5: 1857–1490Google Scholar
- 11.Green SJ, Fleming TR, O’Fallon JR (1987) Policies for study monitoring and interim reporting of results. J Clin Oncol 5: 477–1484Google Scholar
- 12.Groshen S (1992) Antiemetic study design: a discussion of Dr. Olver’s paper. Br J Cancer 66 [Suppl XIX]: S35 – S37Google Scholar
- 13.Italian Group for Antiemetic Research (1997) Delayed emesis induced by moderate emetogenic chemotherapy: do we need to treat all patients? Ann Oncol (in press)Google Scholar
- 17.Morrow GR (1992) Methodology and assessment in clinical anti-emetic research: a meta-analysis of outcome parameters. Br J Cancer 66 [Suppl XIX1: S38 - S41Google Scholar
- 18.Morrow GR, Roscoe JA (1997) Anticipatory nausea and vomiting: models, mechanisms and management. In: Dicato M (ed) Medical Management of Cancer-Treatment Induced Emesis. Martin Dunitz, London, pp 149–166Google Scholar
- 19.Olver IN (1992) Antiemetic study design: desirable objectives, stratifications and analyses. Br J Cancer 66 [Suppl XIX]: S30 - S34Google Scholar